Grey Matters Announces September Opening of its First Brain Dedicated PET Neuroimaging Clinic in the U.S.

Grey Matters touts a U.S. clinic launch, but offers no proof of operational progress.

What the company is saying

Grey Matters Health Inc. claims it will open its flagship NovaScan Neuroimaging Clinic in Davie, Florida next month, positioning this as the first U.S. site dedicated to brain PET scans for Alzheimer’s and other neurodegenerative diseases. The company highlights the use of the FDA-cleared CareMiBrain system, emphasizing 25% less radiation exposure for patients and the absence of a CT requirement. It asserts that brain PET scans for beta-amyloid plaque are reimbursed by Medicare, Medicaid, and private insurers for patients over 65, and references recent FDA-approved Alzheimer’s treatments that require such scans for eligibility. The announcement stresses the novelty and clinical need for dedicated brain PET imaging, citing the limited availability of hospital-based PET/CT scanners for neurological use. Expansion plans are framed as a national rollout of similar clinics. The tone is confident and forward-looking, but the language relies heavily on future intentions and superlative claims without supporting operational or financial detail. CEO Christopher J. Moreau is named, but no institutional partnerships or external validations are referenced.

What the data suggests

The only concrete timeline disclosed is a target to scan the first patient by September 30th, 2026, indicating that clinical operations are not imminent. The 25% reduction in radiation exposure is the sole quantified benefit, but no comparative or clinical data is provided to support this claim. Insurance coverage for beta-amyloid PET scans in patients over 65 is stated, but no patient volume, referral, or reimbursement figures are disclosed. The claim that 45% of PET/CT scanners are hospital-based is presented without context or impact analysis. There are no financial disclosures—no revenue, cost, capital raised, or cash position—nor any evidence of lease agreements, construction progress, or regulatory milestones achieved. The data set is incomplete and does not substantiate readiness to launch, operational capability, or financial viability. All expansion and technology adoption claims remain unverified by disclosed evidence.

Analysis

The announcement is highly forward-looking, with most key claims describing future intentions (clinic opening, first patient scan by 2026, national chain expansion) rather than realised milestones. While the tone is positive and highlights the novelty and benefits of the planned clinic and technology, there is no disclosure of financial results, profitability, or operational metrics. The only concrete timeline is for a first patient scan by September 30th, 2026, indicating a long-term execution horizon. The business plan to open a national chain signals significant capital intensity, but no funding, signed agreements, or committed capital are disclosed. The narrative inflates the signal by emphasizing 'first of its kind' status and broad expansion plans without supporting evidence or measurable progress. The data supports only the existence of a plan and some technology features, not operational or financial achievement.

Risk flags

• ●Execution risk is high, as the company provides no evidence of permits, facility readiness, or regulatory approvals required to open the Davie, Florida clinic. Without these, the projected opening timeline is aspirational rather than actionable.
• ●Financial risk is significant due to the lack of disclosed funding, revenue, or capital commitments. The plan to build a national chain of clinics is capital intensive, but no information on financing sources or runway is given.
• ●Disclosure risk is acute, as the announcement omits key operational data such as lease agreements, construction status, staffing, or patient acquisition plans. This lack of transparency makes it impossible to assess the likelihood of execution.
• ●Market adoption risk exists because the company provides no evidence of referral relationships with neurologists, geriatricians, or primary care physicians, nor any data on patient demand or competitive differentiation.
• ●Technology risk is present, as the claim that the CareMiBrain system is FDA-cleared and ready for use at the clinic is not supported by installation or commissioning evidence. The absence of operational validation increases uncertainty.

Bottom line

Grey Matters Health Inc. is promoting a planned U.S. neuroimaging clinic launch and a national expansion strategy, but provides no operational, financial, or regulatory evidence to support imminent execution. The announcement is dominated by forward-looking statements and superlative claims, with only a single quantified benefit (25% less radiation) and a long-dated first patient scan target. No proof of facility readiness, funding, or market adoption is offered. For investors, this update signals ambition but not progress; the credibility gap is wide, and the risk of non-delivery is high. Actionability is low until the company discloses signed agreements, completed build-outs, or financial commitments. The most important takeaway: this is a promotional update, not a milestone event.

Announcement summary

(CSE: GREY, OTC: AGNPF) Grey Matters Health Inc. announced that it plans to open its flagship NovaScan Neuroimaging Clinics TM location next month in Davie, Florida and conduct a brain PET scan of its first patient by September 30th, 2026. The inaugural clinic will be located at the HCA Florida University Medical Office Building in Davie, on the campus of the HCA Florida University Hospital, and will be the first of its kind in the U.S. to provide brain dedicated PET scans for Alzheimer’s Disease and other neurodegenerative diseases. The clinic will feature the U.S. FDA-cleared CareMiBrain™ system, a new seated diagnostic brain PET scanner that results in 25% less radiation exposure for patients. Brain PET scans for beta-amyloid plaque detection are covered by Medicare, Medicaid and private insurance for those 65+, with referrals from Neurologists, Geriatricians, and Primary Care Physicians. There are two recently U.S. FDA approved monoclonal antibody treatments for AD, Leqembi (Eisai and Biogen) and Kisunla (Eli Lilly), both requiring a positive beta-amyloid brain scan or spinal tap for authorization. The majority of PET/CT scanners, 45% of which are located in hospitals, are primarily used for cancer and cardiac imaging, making timely brain-specific scans challenging. The company projects to open a national chain of its NovaScan Neuroimaging Clinics TM throughout the U.S.

Disagree with this article?